Heart transplantation has emerged as a viable therapeutic strategy for some patients with end-stage heart disease by offering them extended survival and improved quality of life. The cardiologist may refer the patient to a heart transplant center if, the patient health is serious and other treatments are not able to improve things or control patient symptoms. In a heart transplant, a surgery is performed to remove a person's diseased heart and replace it with a healthy heart from a deceased donor. Mostly, it is done on patients who have end-stage heart failure.
Coronary artery disease is the one of the main cause which damages the heart muscle that results in heart failure. There are many diseases which lead to heart failures such as cough-especially at night, poor exercise tolerance, shortness of breath, fatigue, and fluid retention.
According to the registry of the International Society for Heart and Lung Transplantation, approximately 500-600 pediatric heart transplantation procedures are performed globally every year, which represents around 12% of the total number of heart transplants performed. And in 2014, a total number of children heart transplants execute globally was 586. In children, the most often caused of heart failure is occurred owing to a congenital heart defect or a cardiomyopathy.
The Global Heart Transplant Market is expected to grow at a CAGR of 11.2% during the forecast period of 2017-2023.
Business Overview of Worldwide Top Players Listed as:
SynCardia Systems, LLC (U.S.),
HeartWare International Inc.,
Apaxis Medical, Inc.,
Calon Cardio,
Optum Inc. (U.S.),
Thoratec Corporation (U.S.),
CardiacAssist Inc. (U.S.),
CARMAT (France) and others.
Heart Transplant Industry Segmentation:
The global Heart Transplant market is segmented on the basis of types and by the end user.
On the basis of the type, it is segmented into ventricular assist devices, total artificial hearts, and others.
On the basis of the end user, it is segmented into the hospital, cardiac institute and others.